The post Nasdaq and CME Relaunch Crypto Index Partnership appeared on BitcoinEthereumNews.com. Key Points: Nasdaq and CME reintroduce Crypto Index as an institutionalThe post Nasdaq and CME Relaunch Crypto Index Partnership appeared on BitcoinEthereumNews.com. Key Points: Nasdaq and CME reintroduce Crypto Index as an institutional

Nasdaq and CME Relaunch Crypto Index Partnership

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
Key Points:
  • Nasdaq and CME reintroduce Crypto Index as an institutional benchmark.
  • Partnership aims to attract institutional capital via ETFs and derivatives.
  • The index targets large-cap, liquid crypto assets.

Nasdaq Inc. and CME Group announced on January 8, 2026, the reintroduction of the Nasdaq CME Crypto Index (NCI™) as a benchmark for digital asset investments.

This collaboration aims to enhance transparency and reliability in institutional crypto investments, supporting the development of ETFs and other structured products in the burgeoning digital asset market.

Nasdaq CME Crypto Index Targets Institutional Investors

Nasdaq and CME Group have revived the Nasdaq CME Crypto Index as a key tool for institutional investors seeking exposure to a diversified basket of digital assets. Nasdaq CEO Adena Friedman emphasized the demand for transparent and trusted benchmarks. CME’s CEO Terry Duffy highlighted the collaboration’s potential to enhance crypto derivatives and investment products for clients.

Involving top executive decisions, the reintroduction represents a strategic move for both Nasdaq and CME. The index changes include a shift towards supporting the next generation of ETFs and derivatives, aimed at meeting regulatory expectations for transparency and governance. This new benchmark intends to attract institutional capital through products tracking or referencing the index, rather than direct funding.

The market reacted positively, recognizing the announcement as a step forward in institutional crypto adoption. Statements from key figures such as Giovanni Vicioso of CME noted the role of the index in enabling diversified portfolio construction.

Bitcoin Valuation Amid Nasdaq CME Index News

Did you know? The previously launched Nasdaq Crypto Index in 2021 helped lay the groundwork for institutional products, providing early support for ETFs and structured notes, a trend now continuing with the Nasdaq CME Crypto Index.

As of January 10, 2026, Bitcoin (BTC) is valued at $90,471.05 with a market cap of $1.81 trillion, representing 58.52% of market dominance. Trading volume reached $35.39 billion, albeit down by -14.11%. Recent 24-hour price data shows a slight dip of -0.55%, according to CoinMarketCap.

Bitcoin(BTC), daily chart, screenshot on CoinMarketCap at 06:11 UTC on January 10, 2026. Source: CoinMarketCap

Coincu research team highlights the potential growth in institutional investment as the index may increase market stability and attract regulated investment products. The focus on robust governance could align with ongoing regulatory requirements, such as those emphasized in their Latest Analysis.

Source: https://coincu.com/news/nasdaq-cme-crypto-index-partnership/

Market Opportunity
Octavia Logo
Octavia Price(VIA)
$0.0015488
$0.0015488$0.0015488
-1.64%
USD
Octavia (VIA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09